Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07288567 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
A Phase 3 study of Schizophrenia, sponsored by Bristol-Myers Squibb.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 166
- Enrollment target
- 20
- Study locations
NCT07288567: Recruiting Phase 3 study of Schizophrenia, sponsored by Bristol-Myers Squibb.
NCT07288567 is a Phase 3 study of Schizophrenia that is actively recruiting participants, run by Bristol-Myers Squibb. The registered enrollment target is 166 participants, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (24% lower). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07288567, a Phase 3 study of Schizophrenia, is actively recruiting participants, sponsored by Bristol-Myers Squibb.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 166 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
Conditions Studied
Interventions
- DRUG KarXT
- OTHER KarXT Matching Placebo
Study Locations (20)
California
- Local Institution - 0077 - Anaheim
- Local Institution - 0058 - Chino
- Local Institution - 0083 - Redlands
- Local Institution - 0089 - San Francisco
Georgia
- Atlanta Center for Medical Research - Atlanta
- Local Institution - 0106 - Lawrenceville
- Local Institution - 0039 - Stone Mountain
Massachusetts
- Local Institution - 0076 - Boston
- Local Institution - 0100 - Brookline
- Local Institution - 0059 - Worcester
Texas
- Local Institution - 0046 - Garland
- Local Institution - 0090 - McAllen
- Local Institution - 0066 - Spring
Illinois
- Local Institution - 0044 - Chicago
- Local Institution - 0107 - Evanston
Florida
- Local Institution - 0032 - Orlando
Michigan
- Local Institution - 0049 - Highland Park
New York
- Local Institution - 0061 - Great Neck
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2026-01-29 |
| Est. Completion | 2029-12-18 |
| Phase | Phase 3 |
What NCT07288567 shows while recruiting
NCT07288567 is an interventional study that assigns participants to a tested intervention. The registered 166 participants enrollment target is mid-sized for trials with a published cap, below the 218-participant average among 315 other Schizophrenia trials with a reported enrollment target (24% lower).
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which KarXT is the first listed.
NCT07288567 names 20 study sites across 10 states, led by California, Georgia, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07288567 about?
NCT07288567 is a clinical study titled "A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)". The purpose of this study is to evaluate the efficacy and safety of KarXT for treatment of Schizophrenia in adolescents.
What is the current status of trial NCT07288567?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 166 participants. The study started on 2026-01-29. Estimated completion is 2029-12-18.
What conditions does trial NCT07288567 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT07288567?
The interventions under investigation include: KarXT (DRUG), KarXT Matching Placebo (OTHER).
Who is sponsoring clinical trial NCT07288567?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07288567 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07288567's enrollment target sits among peer trials
166 97th of 315 higher than 219 of 315 other Schizophrenia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Schizophrenia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
-
Lumateperone for the Improvement of Apathy in Patients With Psychotic Symptoms.
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02747303 · 166 participants · Phase 2
Frameless Stereotactic Radiosurgery for Intact Brain Metastases
- NCT03806283 · 166 participants
Mechanisms of Pregnancy Vascular Adaptations
- NCT04040452 · 166 participants · Phase 4
Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
- NCT04375813 · 166 participants · Phase 2
Trial of Encapsulated Rapamycin (eRapa) for Bladder Cancer Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI